ArticleCancer management and research2022

Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.

Wenzhen Ge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.